Cosentyx’s positive clinical performance and increasing availability of real-world data will drive its uptake in psoriasis.
By Anna Reyes, Analyst
13 July 2016
I am an Immunology & Inflammation analyst at Datamonitor Healthcare, based in the London office. I joined Datamonito...
Read full bio
Despite physician familiarity with the longstanding anti-tumor necrosis factor (TNF) biologics and the interleukin (IL)-12/23 inhibitor Stelara (ustekinumab; Johnson & Johnson), Cosentyx (secukinumab; Novartis) has made headway in psoriasis since its launch in 2015. Novartis reported 2015 global sales for Cosentyx of $261m. This is primarily due to its promising clinical performance to date, having outperformed Enbrel (etanercept; Amgen/Pfizer/Takeda) and Stelara in its Phase III clinical development program. Key opinion leaders interviewed by Datamonitor Healthcare appear impressed by Cosentyx’s clinical performance to date, particularly in comparison to that of Stelara, but also express the wish to see long-term efficacy data for Cosentyx in the real-world setting.
Datamonitor Healthcare believes that the increasing availability of long-term efficacy and safety data for Cosentyx will drive its uptake in the foreseeable future, allowing it to directly compete with Stelara for the position of the preferred biologic in the post-TNF failure setting, though a subset patients will continue to favor Stelara due to its more convenient dosing regimen. Key opinion leaders stress that while Cosentyx is currently primarily prescribed to patients who have failed treatment with anti-TNF biologics and Stelara, this is likely to change in the future as they gain more experience with the IL-17A inhibitor.
“In the short run I think Cosentyx is better [than Stelara], this has been shown in clinical studies. So, you have a higher rate of clearance, but in terms of the persistence of effect, I mean we need to see what is going to happen because I am not so sure that the superiority is sustained over 2-3 years.”
EU key opinion leader
“Well, for the moment Cosentyx is most prescribed in patients who have failed other biologics [including Stelara], but the situation may change in the future because it has just become available. I think when people will become more confident, they will use it more.”
EU key opinion leader
Datamonitor Healthcare’s Psoriasis: Marketed Drugs provides an in-depth analysis of key marketed drugs for psoriasis across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK), including a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.
Get your free demo of Datamonitor Healthcare today. Simply fill out the form to the right >>>